Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;42(2):51-55.
doi: 10.18773/austprescr.2019.013. Epub 2019 Apr 1.

Influenza: overview on prevention and therapy

Christopher Robson  1   2   3   4   5   6 , Sai Rupa Baskar  1   2   3   4   5   6 , Robert Booy  1   2   3   4   5   6 , Patricia E Ferguson  1   2   3   4   5   6 , Nicole Gilroy  1   2   3   4   5   6 , Jen Kok  1   2   3   4   5   6 , Indy Sandaradura  1   2   3   4   5   6 , Dominic Dwyer  1   2   3   4   5   6
Affiliations
Review

Influenza: overview on prevention and therapy

Christopher Robson et al. Aust Prescr. 2019 Apr.

Erratum in

Abstract

Quadrivalent influenza vaccination is recommended annually for adults and children aged six months to 64 years

High-dose or adjuvanted trivalent vaccines are recommended annually for people 65 years and over

If started early enough, neuraminidase inhibitors reduce symptom duration by approximately one day. Treatment should be considered in patients with severe disease requiring hospitalisation or who are at risk of complications

Chemoprophylaxis is not a substitute for vaccination but can be considered in high-risk individuals with an inadequate or ineffective vaccination status

Keywords: antivirals; chemoprophylaxis; influenza; vaccines.

PubMed Disclaimer

Comment in

References

    1. Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J 2014;33:630-6. 10.1097/INF.0000000000000254 - DOI - PubMed
    1. Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 2013;13:343. 10.1186/1471-2334-13-343 - DOI - PMC - PubMed
    1. van de Witte S, Nauta J, Montomoli E, Weckx J. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. Vaccine 2018;36:6030-8. 10.1016/j.vaccine.2018.04.043 - DOI - PubMed
    1. Treanor JT, Albano FR, Sawlwin DC, Graves Jones A, Airey J, Formica N, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine 2017;35:1856-64. 10.1016/j.vaccine.2017.02.066 - DOI - PubMed
    1. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635-45. 10.1056/NEJMoa1315727 - DOI - PubMed

FURTHER READING

    1. Australian Technical Advisory Group on Immunisation. Australian immunisation handbook [Internet]. Canberra: Department of Health; 2018. https://immunisationhandbook.health.gov.au [cited 2019 Mar 1]
    1. Foo H, Dwyer DE. Rapid tests for the diagnosis of influenza. Aust Prescr 2009;32:64-7. 10.18773/austprescr.2009.034 - DOI

LinkOut - more resources